ART352-L
Augmentation of autograft in spinal fusion surgery
Key Facts
About Ankasa Regenerative Therapeutics
Ankasa Regenerative Therapeutics is a private, San Diego-based biotech founded in 2015, focused on harnessing the Wnt signaling pathway for regenerative medicine. The company has developed a proprietary platform to produce human Wnt proteins for therapeutic use, with its lead candidate, ART352-L, in development to improve outcomes in spinal fusion and other bone reconstructive procedures. Ankasa is pre-revenue and in the pre-clinical/IND-enabling stage, backed by over $25M in venture capital and non-dilutive grant funding from investors like Avalon Ventures and CIRM. Its strategy targets a significant unmet need in bone healing, aiming to reduce revision surgeries and associated healthcare costs.
View full company profile